References
- Jardine I. Podophyllotoxins. Anticancer agents based on natural product models, J M Cassady, J D Douros. Academic Press., New York 1980; 319–51
- Stähelin H, Cerletti A. Experimentelle Ergebnisse mit den Podophyllum-Cytostatica SP-1 und SP-G. Schweiz Med Wochenschr 1964; 94: 1490–502
- Chlud K. 10 Jahre Erfahrung mit Podophyllin in der Behandlung der chronischen Polyartritis. Notabene Medici 1977; 7: 39–41
- Henwood J M, Brogden R N. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990; 39: 438–90
- Chlud K, Prohaska E, Zeitlhofer J, Pfaller C H, Friza B. Immunosuppressive Behandlung der progressiv-chronischen Polyarthritis. Erfahrungen mit einem Antimitotikum aus der Podophyllinreihe (Proresid). Múnch Med Wochenschr 1968; 110: 88–97
- Wawrzynska-Pagowska J, Juszczyk T, Michalski J, Wojcik-Scislowska M. The results of treatment of far-advanced highly active forms of rheumatoid arthritis with immunosuppressive agents: Proresid and endoxan. Reumatologia 1970; 8: 289–97
- Szanto L., Görgenyi F, Benczur M, Reviczky A, Lörincz G, Gömör B. Behandlung der primår chronischen Polyarthritis mit Hilfe des irnmunosuppresiven, zytostatisch wirkenden Podophyllin-Abkömmlings Proresid. Med Welt 1973; 24: 539–41
- Olhagen B. lmmunsuppressiv behandling vid reumatologiska sjukdomar. Läkartidningen 1976; 73: 1628–33
- Hunziker M, Sarkany G, Hunziker H. Die Therapie der primär chronischen Polyarthritis (pcP) mit Proresid. Schweiz Rundsch Med Prax 1977; 66: 1399–401
- Berglund K, Johansson B G, Laurell A B, Sjöholm A, Sturfelt G. Inflammatory parameters in rheumatoid arthritis during and after administration of an anti-mitotic agent (Podophyllum lignan derivatives). Scand J Rheumatol 1978; 7: 61–3
- Meske S, Vogt P, Maly F E, Müller W. Die immunmodu-lierende Behandlung der chronischen Polyarthritis mit Podophyllin (Podophyllinsäureäthyl-hydrazid, Proresid). Akt Rheumatol 1985; 10: 1–3
- Larsen A. Retrospective survey of second line drugs and corticosteroids in 184 patients with rheumatoid arthritis. Internationale Ischia-Tage “Rheuma in Forschung und Praxis”. Ischia, Italy 12–26 Sept 1987. 2nd ed. Conpharm AB, KarlstadSweden 1987; 11–23
- Lysholm J, Weitoft T. Proresid in the long-term treatment of rheumatoid arthritis. Scand J Rheumatol 1988; 17: 465–8
- Larsen A. Prored - A valuable and well-tolerated drug?. Scand J Rheumatol 1989; 18: 245
- Lysholm J, Weitoft T. Treatment of rheumatoid patients with proresid1. Scand J Rheumatol 1990; 19: 170
- Bendix G, Bjelle A. Outcome of parenteral gold therapy in RA patients: A comparison between two periods using life-table analysis. Br J Rheumatol 1991; 30: 407–12
- Eriksson B. Personal communication
- Ropes M W, Bennett G A, Cobb S, Jacox R, Jessar R A. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Kheum Dis 1958; 9: 175–6
- Pinals R S, Masi A T, Larscn R A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308–15
- Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940; 7: 172–88
- Bergquist R. Immunofluorescence. Evaluation of techniques and reagents with special reference to methodological standardization. (Thesis). Karolinska institutet, Stockholm 1974
- Mattsson B. Cancer registration in Sweden. Studies of completeness and validity of incidence and mortality registers. (Thesis). Karolinska institutet, Stockholm 1984
- Bradley J W. Distribution-free statistical tests. Prentice-Hall, London 1968; 68–86
- Peto R, Pike M C, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Br J Cancer 1977; 35: 1–39
- Merck C, Angervall L, Kindblom L G, Odén A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. Acta Pathol Microbiol lmmunol Scand. Section A 1983; 81(Suppl 282)
- Breslow N E, Day N E. Statistical methods in cancer research. IARC Sci Publ No 32, Lyon 1987; Vol II.: 131–5
- Lehmann E L. Testing statistical hypotheses. Wiley, New York 1959; 79–81
- Richter J A, Runge L A, Pinals R S. Oates. RP. Analysis of treatment terminations with gold and antimalarial conipounds in rheumatoid arthritis. J Rheumatol 1980; 7: 153–9
- Sambrook P N, Browne C D, Champion G D, Day K O, Vallance J B, Warwick N. Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis. J Rheumatol 1982; 9: 932–4
- Thompson P W, Kirwan J R, Barnes C G. Practical results of treatment with disease-modifying antirheumatoid drugs. Br J Kheumatol 1985; 24: 167–75
- Situnayake R D, Grindulis K A, McConkey B. Long term treatment of rheumatoid arthritis with sulphasalazinc gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987; 46: 177–83
- Ahlmén M, Ahlmén J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987; 6: 27–38
- Weitoft T, Lysholm J. Side effects of Proresid in the treatment of chronic arthritis. Scand J Rheumatol 1988; 17: 63–6
- Rosén B. Personal communication 1992
- Larsen A, Petersqon I, Svensson B. Podophyllum derivatives (CPH 82) compared with placebo in the treatment of rheumatoid arthritis. Br J Rheumatol 1980; 28: 124–7
- Berglund K. Postal enkät avseende Proresid (Postal questionnaire regarding Proresid. In Swedish) 1984